We are reporting from the 2022 ASH Annual Meeting!
Get ready, because we are presenting the top news presented each day during the meeting—and soon we’ll speak with Dr. Catherine Coombs for updates in chronic lymphocytic leukemia, Dr. Nelli Bejanyan on the latest in graft-vs-host disease, and Dr. Aaron Gerds on new data in myeloproliferative neoplasms.
Welcome to OncLive News Network! I’m Gina Mauro.
Preliminary phase 1 data showed that the highly selective BCL-2 inhibitor BGB-11417 alone or in combination with zanubrutinib, was well-tolerated in most patients, and the agent was found to have encouraging responses in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
In a large real-world study, patients with CLL who were treated with frontline acalabrutinib were significantly more likely to start a next treatment or add or intensify therapy vs treated with frontline ibrutinib. Real-world treatment patterns also suggest a higher propensity to add an anti-CD20 antibody to acalabrutinib versus ibrutinib in first-line CLL.
In follicular lymphoma, data from the phase 2 HOVON110 or Rebel trial showed that there were high response rates with lenalidomide and rituximab with and without bendamustine in patients with relapsed/refractory disease. However, there were low CT-based complete response rates with both treatments.
Birtamimab demonstrated a significant survival benefit in patients with Mayo stage IV amyloid light chain amyloidosis in the phase 3 VITAL study, even after adjusting for baseline variables. These data are hoped to be confirmed in the AFFIRM-AL trial, which is active and enrolling.
That’s all for today and a wrap on the 2022 ASH Annual Meeting. Thank you for watching OncLive News Network: On Location, I’m Gina Mauro.